Meeting
2016 ASCO Annual Meeting
POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm).
Authors
Talia Golan
The Oncology Institute Sheba Medical Center, Tel-Hashomer, Israel
Talia Golan , Do-Youn Oh , Michele Reni , Teresa Mercade Macarulla , Giampaolo Tortora , Michael J. Hall , Anke C. Reinacher-Schick , Christophe Borg , Daniel Hochhauser , Thomas Walter , Howard S. Hochster , Nigel Baker , Gershon Y. Locker , Hedy L. Kindler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT02184195
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS4152)
DOI
10.1200/JCO.2016.34.15_suppl.TPS4152
Abstract #
TPS4152
Poster Bd #
133b
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2 mutation (gBRCAm) who have not progressed following first-line chemotherapy.
First Author: Hedy Lee Kindler
Poster
2018 ASCO Annual Meeting
Geographic and ethnic heterogeneity in the BRCA1/2 pre-screening population for the randomized phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC).
First Author: Talia Golan
Poster
2016 ASCO Annual Meeting
SOLO3: A randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCA1/2 mutation (gBRCAm).
First Author: Elizabeth S. Lowe
Poster
2023 ASCO Annual Meeting
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.
First Author: Vincent Chung